Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:569392.
doi: 10.1155/2015/569392. Epub 2015 Jun 10.

FoxO proteins in the nervous system

Kenneth Maiese  1
Affiliations
Review

FoxO proteins in the nervous system

Kenneth Maiese. Anal Cell Pathol (Amst). 2015.

Abstract

Acute as well as chronic disorders of the nervous system lead to significant morbidity and mortality for millions of individuals globally. Given the ability to govern stem cell proliferation and differentiated cell survival, mammalian forkhead transcription factors of the forkhead box class O (FoxO) are increasingly being identified as potential targets for disorders of the nervous system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and auditory neuronal disease. FoxO proteins are present throughout the body, but they are selectively expressed in the nervous system and have diverse biological functions. The forkhead O class transcription factors interface with an array of signal transduction pathways that include protein kinase B (Akt), serum- and glucocorticoid-inducible protein kinase (SgK), IκB kinase (IKK), silent mating type information regulation 2 homolog 1 (S. cerevisiae) (SIRT1), growth factors, and Wnt signaling that can determine the activity and integrity of FoxO proteins. Ultimately, there exists a complex interplay between FoxO proteins and their signal transduction pathways that can significantly impact programmed cell death pathways of apoptosis and autophagy as well as the development of clinical strategies for the treatment of neurodegenerative disorders.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Filley C. M., Rollins Y. D., Alan Anderson C., et al. The genetics of very early onset Alzheimer disease. Cognitive and Behavioral Neurology. 2007;20(3):149–156. doi: 10.1097/wnn.0b013e318145a8c8. - DOI - PubMed
    1. Maiese K. Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Annals of Medicine. 2014;46(8):587–596. doi: 10.3109/07853890.2014.941921. - DOI - PMC - PubMed
    1. Maiese K. Cutting through the complexities of mTOR for the treatment of stroke. Current Neurovascular Research. 2014;11(2):177–186. doi: 10.2174/1567202611666140408104831. - DOI - PMC - PubMed
    1. Pergola P. E., White C. L., Szychowski J. M., et al. Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned. American Journal of Hypertension. 2014;27(8):1052–1060. doi: 10.1093/ajh/hpu027. - DOI - PMC - PubMed
    1. Pineda D., Ampurdanés C., Medina M. G., et al. Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors. Glia. 2012;60(4):526–540. doi: 10.1002/glia.22284. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources